Newsroom | 75176 results

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Southern Research has been awarded an $8 million grant from the National Institutes of Health (NIH) to build the Translational Hub for Research, Innovation, Validation, and Excellence (THRIVE). THRIVE will be a national shared-use biomedical research facility focused on accelerating the development, validation, and adoption of new approach methodologies (NAMs), a broad range of laboratory, computational, and data-driven approaches designed to better reflect hu...

AMES, Iowa--(BUSINESS WIRE)--Peak 301, a topically-applied solution designed to extend the life of asphalt shingles, has established itself as the leading product of its kind in the growing roof rejuvenation market. A new applicator group — Peak 301 Pros — has united around the product to meet the demand of homeowners and business owners, while providing additional opportunities within the home services sector.Peak 301 Pros is a nationwide group that equips businesses to offer roof rejuvenation...

MANHASSET, N.Y.--(BUSINESS WIRE)--The life-altering power of bioelectronic medicine took center stage this week as Northwell Health’s Feinstein Institutes for Medical Research hosted its seventh Bioelectronic Medicine Summit on September 28-29, 2026, at The Lighthouse at Chelsea Piers in New York City. The sold-out international scientific symposium, co-chaired by Eric H. Chang, PhD, associate professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Christopher Puleo...

GALASHIELS, Schottland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, eine hundertprozentige Tochtergesellschaft der Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), gab heute die endgültigen Ergebnisse der deutschen MINT-Studie bekannt, in der Mogamulizumab bei Patienten mit Mycosis fungoides (MF) und dem Sézary-Syndrom (SS) untersucht wurde. Die Ergebnisse, die auf der Jahrestagung 2026 der Cutaneous Lymphoma Tumour Group (EORTC-CLTG) der Europäischen Organisation für Krebsf...

GALASHIELS, Scozia, e MARLOW, Inghilterra--(BUSINESS WIRE)--Kyowa Kirin International plc, una sussidiaria controllata al 100% da Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), oggi ha annunciato i risultati finali dello studio MINT condotto in Germania per la valutazione di mogamulizumab nei pazienti affetti da micosi fungoide (MF) e dalla sindrome di Sézary (SS). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono...

GALASHIELS, Schotland & MARLOW, Engeland--(BUSINESS WIRE)--Kyowa Kirin International plc, een dochteronderneming volledig in handen van Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), maakte vandaag de definitieve resultaten bekend uit de Duitse MINT-studie ter beoordeling van mogamulizumab bij patiënten met mycosis fungoides (MF) en sézarysyndroom (SS). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met...

BOSTON--(BUSINESS WIRE)--Time is running out to win a once-in-a-lifetime trip to Boston to meet Mark Rober, the former NASA engineer behind the most-watched science channel on YouTube, with more than 18 billion views and 83 million subscribers. Entries for the Museum of Science's Mark Rober sweepstakes close at 12:00 PM ET on October 13. One winner and a guest will travel to Boston to see Live with Mark Rober on Saturday, October 24, an event that sold out its 500 seats in under two minutes, an...

MANHASSET, N.Y.--(BUSINESS WIRE)--Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that causes painful inflammation throughout the body. Cynthia Aranow, MD, professor in the Institute of Molecular Medicine, Lupus Center of Excellence at The Feinstein Institutes for Medical Research, is leading a novel clinical trial studying the therapeutic potential of non-invasive vagus nerve stimulation (VNS) to curb lupus-related pain and fatigue. Study participants receive daily, brief st...

CAMBRIDGE, England--(BUSINESS WIRE)--Amphista Therapeutics Limited (‘Amphista’ or ‘the Company’), a leader in the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced dosing of the first patient in a Phase 1 trial for its lead candidate, AMX-883. Initiated following authorization from the U.S. Food and Drug Administration in June 2026, the BRAMLIE trial will investigate the safety, pharmacokinetics, and preliminary efficacy of AMX-883 mon...

中国苏州--(BUSINESS WIRE)--(美国商业资讯)-- 全球定制聚合物解决方案领导者Americhem于9月28日举行了其位于苏州的全新洁净配混设施启用仪式。此项投资进一步提升了Americhem服务中国、亚太地区以及在该区域开展生产制造业务的全球客户的能力。 该设施专为满足严苛医疗器械应用所需的ISO 13485和cGMP要求而设计，在Americhem美国和丹麦现有认证能力基础上，进一步扩展了其全球洁净配混网络。该设施使可靠的生产能力、稳定一致的产品质量以及专业技术支持更加贴近医疗健康OEM客户，助力其开发和制造受严格监管的产品。 “苏州设施的扩建进一步增强了我们服务全球客户的能力，同时将Americhem的技术专长和制造能力带到亚太地区客户身边，” Americhem首席执行官（CEO）John Richard表示。“这项投资体现了我们对全球供应连续性、区域响应能力以及医疗健康客户所依赖的高质量标准的坚定承诺。” “我们的客户需要的不仅仅是本地化生产能力。他们更需要一位能够理解其技术要求、质量期望和增长目标的材料解决方案合作伙伴，” Americhem亚太区副总裁 R...